These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 23456384)
1. Body surface area predicts plasma oxaliplatin and pharmacokinetic advantage in hyperthermic intraoperative intraperitoneal chemotherapy. Leinwand JC; Bates GE; Allendorf JD; Chabot JA; Lewin SN; Taub RN Ann Surg Oncol; 2013 Apr; 20(4):1101-4. PubMed ID: 23456384 [TBL] [Abstract][Full Text] [Related]
2. Effect of perfusion temperature on glucose and electrolyte transport during hyperthermic intraperitoneal chemoperfusion (HIPEC) with oxaliplatin. Ceelen W; De Somer F; Van Nieuwenhove Y; Vande Putte D; Pattyn P Eur J Surg Oncol; 2013 Jul; 39(7):754-9. PubMed ID: 22878060 [TBL] [Abstract][Full Text] [Related]
3. Hyperthermic intraperitoneal chemotherapy with oxaliplatin as treatment for peritoneal carcinomatosis arising from the appendix and pseudomyxoma peritonei: a survival analysis. Marcotte E; Dubé P; Drolet P; Mitchell A; Frenette S; Leblanc G; Leclerc YE; Sideris L World J Surg Oncol; 2014 Nov; 12():332. PubMed ID: 25380618 [TBL] [Abstract][Full Text] [Related]
4. Treatment of peritoneal carcinomatosis from colonic cancer by cytoreduction, peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC). Experience of ten years. Vaira M; Cioppa T; D'Amico S; de Marco G; D'Alessandro M; Fiorentini G; De Simone M In Vivo; 2010; 24(1):79-84. PubMed ID: 20133981 [TBL] [Abstract][Full Text] [Related]
5. Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for limited peritoneal metastasis. The PSOGI international collaborative registry. Arjona-Sanchez A; Aziz O; Passot G; Salti G; Esquivel J; Van der Speeten K; Piso P; Nedelcut DS; Sommariva A; Yonemura Y; Turaga K; Selvasekar CR; Rodriguez-Ortiz L; Sanchez-Hidalgo JM; Casado-Adam A; Rufian-Peña S; Briceño J; Glehen O Eur J Surg Oncol; 2021 Jun; 47(6):1420-1426. PubMed ID: 33298341 [TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of peritoneal, plasma ultrafiltrated and protein-bound oxaliplatin concentrations in patients with disseminated peritoneal cancer after intraperitoneal hyperthermic chemoperfusion of oxaliplatin following cytoreductive surgery: correlation between oxaliplatin exposure and thrombocytopenia. Chalret du Rieu Q; White-Koning M; Picaud L; Lochon I; Marsili S; Gladieff L; Chatelut E; Ferron G Cancer Chemother Pharmacol; 2014 Sep; 74(3):571-82. PubMed ID: 25053386 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of oxaliplatin during open versus laparoscopically assisted heated intraoperative intraperitoneal chemotherapy (HIPEC): an experimental study. Gesson-Paute A; Ferron G; Thomas F; de Lara EC; Chatelut E; Querleu D Ann Surg Oncol; 2008 Jan; 15(1):339-44. PubMed ID: 17943387 [TBL] [Abstract][Full Text] [Related]
8. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. Prada-Villaverde A; Esquivel J; Lowy AM; Markman M; Chua T; Pelz J; Baratti D; Baumgartner JM; Berri R; Bretcha-Boix P; Deraco M; Flores-Ayala G; Glehen O; Gomez-Portilla A; González-Moreno S; Goodman M; Halkia E; Kusamura S; Moller M; Passot G; Pocard M; Salti G; Sardi A; Senthil M; Spiliotis J; Torres-Melero J; Turaga K; Trout R J Surg Oncol; 2014 Dec; 110(7):779-85. PubMed ID: 25088304 [TBL] [Abstract][Full Text] [Related]
9. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Elias D; Bonnay M; Puizillou JM; Antoun S; Demirdjian S; El OA; Pignon JP; Drouard-Troalen L; Ouellet JF; Ducreux M Ann Oncol; 2002 Feb; 13(2):267-72. PubMed ID: 11886004 [TBL] [Abstract][Full Text] [Related]
10. Obesity and peritoneal surface disease: outcomes after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for appendiceal and colon primary tumors. Votanopoulos KI; Swords DS; Swett KR; Randle RW; Shen P; Stewart JH; Levine EA Ann Surg Oncol; 2013 Nov; 20(12):3899-904. PubMed ID: 23800899 [TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics of Oxaliplatin-Derived Platinum Compounds During Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Emerging Aspect Supporting the Rational Design of Treatment Protocols. Löffler MW; Schuster H; Zeck A; Quilitz N; Weinreich J; Tolios A; Haen SP; Horvath P; Löb S; Rammensee HG; Königsrainer I; Königsrainer A; Beckert S Ann Surg Oncol; 2017 Jun; 24(6):1650-1657. PubMed ID: 28160138 [TBL] [Abstract][Full Text] [Related]
12. Impact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE Study. Malgras B; Gayat E; Aoun O; Lo Dico R; Eveno C; Pautrat K; Delhorme JB; Passot G; Marchal F; Sgarbura O; Ferron G; Goéré D; Andre T; Pocard M; Ann Surg Oncol; 2018 Oct; 25(11):3271-3279. PubMed ID: 29978366 [TBL] [Abstract][Full Text] [Related]
13. Impact of Laparotomy and Intraperitoneal Hyperthermic Instillation (LIHI) on the oxaliplatin pharmacokinetics after intravenous administration in Wistar rats. Mas-Fuster MI; Ramon-Lopez A; Lacueva J; Compañ A; Más-Serrano P; Nalda-Molina R Cancer Chemother Pharmacol; 2017 Mar; 79(3):621-627. PubMed ID: 28168311 [TBL] [Abstract][Full Text] [Related]
14. Body surface area-based vs concentration-based perioperative intraperitoneal chemotherapy after optimal cytoreductive surgery in colorectal peritoneal surface malignancy treatment: COBOX trial. Lemoine L; Thijssen E; Carleer R; Geboers K; Sugarbaker P; van der Speeten K J Surg Oncol; 2019 Jun; 119(7):999-1010. PubMed ID: 30838646 [TBL] [Abstract][Full Text] [Related]
15. A phase I trial of oxaliplatin for intraperitoneal hyperthermic chemoperfusion for the treatment of peritoneal surface dissemination from colorectal and appendiceal cancers. Stewart JH; Shen P; Russell G; Fenstermaker J; McWilliams L; Coldrun FM; Levine KE; Jones BT; Levine EA Ann Surg Oncol; 2008 Aug; 15(8):2137-45. PubMed ID: 18493824 [TBL] [Abstract][Full Text] [Related]
16. Systemic exposure of the parent drug oxaliplatin during hyperthermic intraperitoneal perfusion. Mahteme H; Wallin I; Glimelius B; Påhlman L; Ehrsson H Eur J Clin Pharmacol; 2008 Sep; 64(9):907-11. PubMed ID: 18563401 [TBL] [Abstract][Full Text] [Related]
18. The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study. Hompes D; D'Hoore A; Van Cutsem E; Fieuws S; Ceelen W; Peeters M; Van der Speeten K; Bertrand C; Legendre H; Kerger J Ann Surg Oncol; 2012 Jul; 19(7):2186-94. PubMed ID: 22395983 [TBL] [Abstract][Full Text] [Related]
19. Hemophagocytic syndrome: an unusual and underestimated complication of cytoreduction surgery with heated intraperitoneal oxaliplatin. Schwarz L; Bridoux V; Veber B; Oksenhendler E; Royon V; Michot F; Tuech JJ Ann Surg Oncol; 2013 Nov; 20(12):3919-26. PubMed ID: 23838919 [TBL] [Abstract][Full Text] [Related]
20. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei and appendix tumours in elderly patients: Is it justified? López-López V; Cascales-Campos PA; Gil E; Arevalo J; Gonzalez A; Gil J; Muñoz-Casares FC; Melero JT; Barrios P; Morales R; Ramos I; Ortega G; Camps B; González-Bayón L; Bretcha-Boix P; Farré-Alegre J; González-Moreno S; Parrilla P Clin Transl Oncol; 2017 Nov; 19(11):1388-1392. PubMed ID: 28812240 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]